Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-FSH or anti-FSHR antibody
The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders.
1. A method for inhibiting osteoclast differentiation in a cell population comprising at least one osteoclast or at least one osteoclast precursor cell, said method comprising providing an anti-follicle stimulating hormone (FSH) antibody or an anti-follicle stimulating hormone receptor (FSHR) antibody to said cell population, thereby inhibiting differentiation of said osteoclast or said osteoclast precursor cell.
2. The method of claim 1 , wherein said cell population comprises said at least one osteoclast precursor cell.
3. The method of claim 1 , wherein said cell population comprises said at least one osteoclast.
4. The method of claim 1 , wherein said cell population is in vivo and comprises said at least one osteoclast, and wherein said anti-FSH antibody or said anti-FSHR antibody is provided to the vicinity of said at least one osteoclast in vivo.
5. A method for decreasing osteoclast-mediated bone resorption in a patient having a bone loss disorder caused by increased bone resorption, comprising administering a therapeutically effective amount of a composition comprising an anti-follicle stimulating hormone (FSH) antibody or an anti-follicle stimulating hormone receptor (FSHR) antibody to said patient.
6. The method of claim 5 , wherein said bone loss disorder is selected from the group consisting of osteoporosis, Paget's disease, periodontitis, hypercalcemia, osteonecrosis, osteosarcoma, osteolyic metastases, familial expansile osteolysis, prosthetic loosening, periprostetic osteolysis, juxtaarticular bone destruction in rheumatoid arthritis and cleiodocranial dysplasia (CCD).
7. A method for decreasing osteoclast-mediated bone resorption in a patient having a bone loss disorder caused by increased bone resorption, the method comprising administering a composition comprising a therapeutically effective amount of an anti-follicle stimulating hormone (FSH) antibody to said patient.
8. The method of claim 7 wherein the antibody is a monoclonal antibody.
9. The method of claim 7 wherein the antibody is a humanized antibody.
10. The method of claim 7 wherein the antibody is a human antibody.